Dr. Harris is chair of dermatology, director of the Autoimmune Therapeutics Institute, and director of the Vitiligo Clinic and Research Center at UMass Chan Medical School. He is a dermatologist and physician-scientist, caring for patients in a vitiligo specialty clinic and running a research laboratory focused on understanding disease pathogenesis and developing new treatments. His group integrates basic, translational, and clinical research strategies to accomplish this. As a result, clinical trials in vitiligo have shown success. Dr. Harris founded Villaris Therapeutics (acquired by Incyte in 2022) and 3 other companies to develop treatments for inflammatory skin diseases.
